Table 2. 90Y-TARE and treatment associated data.
| Characteristics | All patients | PFS pPET-RadScore | OS-pPET-RadScore | ||||
|---|---|---|---|---|---|---|---|
| Low-risk group | High-risk group | P | Low-risk group | High-risk group | P | ||
| Subjects, n | 47 | 42 | 5 | 33 | 14 | ||
| 90Y-TARE data | |||||||
| 90Y-resin | 31 (66) | 27 (64.3) | 4 (80) | 0.48 | 19 (57.6) | 12 (85.7) | 0.06 |
| 90Y-glass | 16 (34) | 15 (35.7) | 1 (20) | 0.48 | 14 (42.4) | 2 (14.3) | 0.06 |
| 90Y-administered activity, GBq | 1.6 (1.2–2.5) | 1.5 (1.1–2.1) | 2.4 (1.6–2.5) | 0.26 | 1.5 (1.1–2.0) | 1.9 (1.5–2.6) | 0.22 |
| TV based on 99mTc-MAA SPECT/CT, cm3 | 170 (80–615) | 157 (80–600) | 430 (220–560) | 0.65 | 150 (60–300) | 435 (148–646) | 0.15 |
| 90Y-administered activity per unit of TV, MBq/cm3 | 7.3 (4.9–16.2) | 7.9 (4.9–16.3) | 6.4 (5.6–7.3) | 0.81 | 9.8 (5.2–16.7) | 6.0 (3.9–8.4) | 0.31 |
| 90Y-tumor liver absorbed dose, Gy | 170 (115–281) | 170 (114–286) | 205 (155–230) | 0.86 | 170 (115–290) | 159 (119–224) | 0.91 |
| 90Y-normal liver absorbed dose, Gy | 40 (22–63) | 40 (21–64) | 36 (30–54) | 0.33 | 43 (24–70) | 33 (23–50) | 0.05 |
| Unilobar | 26 (55.4) | 24 (57.1) | 2 (40) | 0.47 | 20 (60.6) | 6 (42.9) | 0.26 |
| Bilobar | 8 (17) | 6 (14.3) | 2 (40) | 0.15 | 5 (15.2) | 3 (21.4) | 0.60 |
| Segmental | 8 (17) | 7 (16.7) | 1 (20) | 0.85 | 5 (15.2) | 3 (21.4) | 0.60 |
| Lobar and segmental | 5 (10.6) | 5 (11.9) | 0 (0) | 0.41 | 3 (9.1) | 2 (14.3) | 0.60 |
| Treatments pre-90Y-TARE | |||||||
| Targeted therapy (Sorafenib) | 4 (8.5) | 3 (7.1) | 1 (20) | 0.45 | 3 (9.1) | 1 (7.1) | 0.55 |
| Embolization | 3 (6.4) | 3 (7.1) | 0 (0) | 0.54 | 3 (9.1) | 0 (0) | 0.24 |
| TACE | 11 (23.4) | 10 (23.8) | 1 (20) | 0.85 | 9 (27.3) | 2 (14.3) | 0.34 |
| Radiofrequency ablation | 6 (12.8) | 6 (14.3) | 0 (0) | 0.37 | 5 (15.2) | 1 (7.1) | 0.45 |
| Ethanol ablation | 3 (6.4) | 3 (7.1) | 0 (0) | 0.54 | 2 (6.1) | 1 (7.1) | 0.24 |
| 90Y-TARE | 1 (2.1) | 1 (2.4) | 0 (0) | 0.73 | 1 (3) | 0 (0) | 0.51 |
| Treatments after 90Y-TARE | |||||||
| Targeted therapy (Sorafenib) | 4 (8.5) | 3 (7.1) | 1 (20) | 0.33 | 3 (9.1) | 1 (7.1) | 0.83 |
| Embolization | 1 (2.1) | 1 (2.4) | 0 (0) | 0.73 | 1 (3) | 0 (0) | 0.51 |
| TACE | 10 (21.3) | 10 (23.8) | 0 (0) | 0.22 | 9 (27.3) | 1 (7.1) | 0.12 |
| Radiofrequency ablation | 7 (14.9) | 7 (16.7) | 0 (0) | 0.32 | 6 (18.2) | 1 (7.1) | 0.33 |
| Ethanol ablation | 1 (2.1) | 1 (2.4) | 0 (0) | 0.73 | 1 (3) | 0 (0) | 0.51 |
| Hepatectomy | 1 (2.1) | 1 (2.4) | 0 (0) | 0.73 | 1 (3) | 0 (0) | 0.51 |
| 90Y-TARE | 1 (2.1) | 1 (2.4) | 0 (0) | 0.73 | 1 (3) | 0 (0) | 0.51 |
Values are median (25th; 75th interquartile range) or n (%).
TV, tumor volume; TARE, transarterial radioembolization; TACE, transarterial chemoembolization; SPECT/CT, single-photon emission computed tomography 99mTC-MAA, technetium-macroaggregated albumin.